相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N plus C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).
Amishi Yogesh Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care
Daniel Castellano et al.
CANCER TREATMENT REVIEWS (2020)
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Elie Rassy et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma
Linh Nguyen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Daan P. Hurkmans et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Steven Lacy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types
Steven Lacy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis
C. Liu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Medical treatment of renal cancer: new horizons
Basma Greef et al.
BRITISH JOURNAL OF CANCER (2016)
分享论文
